🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522932-15-00
Ongoing Phase I

A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

2025-522932-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Glaxosmithkline Research & Development Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
23/03/2026
Enrollment target
18
Sites
Germany, France, Italy, Spain, Poland

Condition studied

Systemic Lupus Erythematosus

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522932-15-00 on CTIS ↗ ← All trials in the EU